Actively Recruiting
Long-term Monitoring Study of Patients Treated With ARD103 CAR-T Cell Therapy in a Prior Phase 12 Trial
Led by ARCE Therapeutics, Inc. · Updated on 2026-10-30
49
Participants Needed
3
Research Sites
22 weeks
Total Duration
AI-Summary
What This Trial Is About
This research focuses on participants with relapsed or refractory Acute Myeloid Leukemia AML or Myelodysplastic Syndrome MDS who have previously received ARD103 CAR-T cell therapies. The study aims to assess the long-term safety of ARD103 cellular treatments by monitoring participants for adverse events related to this therapy over an extended period. Participants who completed or discontinued early from a prior 24-month interventional study involving ARD103 will be invited to join this long-term follow-up LTFU study. This observational study does not involve administering any investigational product. Instead, it tracks safety outcomes for up to 15 years after ARD103 treatment, including the incidence and duration of adverse events, serious adverse events, and adverse events of special interest. During the LTFU study, participants will be regularly monitored without receiving additional treatment. Researchers will collect data on any therapy-related health issues and evaluate long-term efficacy outcomes. The total participation period can extend up to 15 years post-treatment to thoroughly understand the long-term safety profile of ARD103 CAR-T cell therapy.
CONDITIONS
Brief Title
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
Research Team
A
ARCE Therapeutics, Inc ARCE
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here